DOP052. Ozanimod induces histological response and remission: results from the TOUCHSTONE study, a randomised, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate-to-severe ulcerative colitis
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.